Why the study?
Do antiarrhythmic compounds with atrial selectivity restore sinus rhythm with reduced risk of ventricular proarrhythmia in patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Design
Review
Authors
Loading...
Atrial-selective targets merit preclinical pursuit; leaves open whether compounds safely restore sinus rhythm in atrial fibrillation.
Do antiarrhythmic compounds with atrial selectivity restore sinus rhythm with reduced risk of ventricular proarrhythmia in patients with atrial fibrillation?
Atrial-selective antiarrhythmic compounds offer a promising therapeutic strategy for managing atrial fibrillation by potentially reducing the risk of ventricular proarrhythmia associated with traditional agents.
Brian F. McBride (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: